Drug Profile
TOP 1630
Alternative Names: TOP1630Latest Information Update: 07 Dec 2022
Price :
$50
*
At a glance
- Originator TopiVert
- Class Anti-inflammatories; Eye disorder therapies; Small molecules
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors; Protein kinase inhibitors; Src-Family kinase inhibitors; Syk kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Dry eyes
Highest Development Phases
- No development reported Dry eyes
Most Recent Events
- 07 Dec 2022 No development reported - Phase-II/III for Dry eyes in USA (Topical)
- 28 Apr 2020 No recent reports of development identified for preclinical development in Dry-eyes in United Kingdom (Topical, Drops)
- 14 May 2019 Topivert Pharma completes the phase II/III THEIA-1 trial in Dry eyes in USA (NCT03833388)